Li Shen Haiyan Chen Qichun Wei
10.3389/fimmu.2021.621858
Front Immunol
2021 Apr 15;12:621858.
case report immune-therapy–related toxicity events immunotherapy pembrolizumab thymoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/33936037/
Antibodies, Monoclonal, Humanized / therapeutic use Drug-Related Side Effects and Adverse Reactions / diagnosis Hypothyroidism / diagnosis Immune Checkpoint Inhibitors / therapeutic use Myocarditis / diagnosis Thymoma / drug therapy Thymus Neoplasms / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use Drug-Related Side Effects and Adverse Reactions / diagnosis Hypothyroidism / diagnosis Immune Checkpoint Inhibitors / therapeutic use Myocarditis / diagnosis Thymoma / drug therapy Thymus Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized / adverse effects Drug Tapering Female Humans Hypothyroidism / etiology Immune Checkpoint Inhibitors / adverse effects Middle Aged Myocarditis / etiology Neoplasm Metastasis Programmed Cell Death 1 Receptor / antagonists & inhibitors Recovery of Function Remission Induction Thymoma / complications Thymus Neoplasms / complications Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors Programmed Cell Death 1 Receptor pembrolizumab
PMC8082155
33936037
Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report
2021